Supernus Pharmaceuticals, Inc. - Common Stock (SUPN)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 885% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 3/9 — signs of financial weakness
- ROE of 0.4% — below-average profitability
- Revenue growing at 9% annually
Supernus Pharmaceuticals, Inc. - Common Stock (SUPN) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $3.1 billion . Key value metrics: P/E ratio 756.3, P/B ratio 2.89, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Supernus Pharmaceuticals, Inc. - Common Stock — Fundamental Analysis Summary
Supernus Pharmaceuticals, Inc. - Common Stock (SUPN) is currently trading 885% above its Graham Number of $5.40, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 756.3x.
On financial health, SUPN shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and modest return on equity of 0.4% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.37.
StockPik's composite Value Score for SUPN is 47/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
SUPN reports a high gross margin of 89.9% (sector average: 33.5%) and a negative operating margin of -2.6%.
SUPN shows revenue growing at 9% year-over-year, with earnings declining at 152%.